A large GWAS meta-analysis of more than 640,000 individuals identified a rare noncoding variant, rs17834140‑T, that reduces clonal hematopoiesis (CHIP) and lowers blood-cancer risk. The protective allele weakens MSI2 (musashi RNA binding protein 2) activity by disrupting a GATA‑2 transcription factor binding site, slowing expansion of mutated hematopoietic stem cell clones. The study, led by Vijay G. Sankaran’s lab at Harvard Medical School and published in Science, links inherited regulatory variation to resilience against age-related clonal expansion. The authors propose MSI2 modulation as a potential therapeutic axis; independent perspectives noted MSI2-targeting small molecules are already in preclinical development.